tetano
Editor, Senior Moderator
J Clin Transl Hepatol
. 2021 Apr 28;9(2):239-246.
doi: 10.14218/JCTH.2020.00126. Epub 2021 Apr 25.
Progress in the Clinical Features and Pathogenesis of Abnormal Liver Enzymes in Coronavirus Disease 2019
Haiyan Wu[SUP] 1 [/SUP], Shuzhong Liu[SUP] 1 [/SUP], Hesheng Luo[SUP] 1 [/SUP], Mingkai Chen[SUP] 1 [/SUP]
Affiliations
Abstract
With the rapid development of research on coronavirus disease 2019 (COVID-19), more and more attention has been drawn to its damage to extrapulmonary organs. There are increasing lines of evidence showing that liver injury is closely related to the severity of COVID-19, which may have an adverse impact on the progression and prognosis of the patients. What is more, severe acute respiratory syndrome coronavirus-2 infection, cytokine storm, ischemia/hypoxia reperfusion injury, aggravation of the primary liver disease and drug-induced liver injury may all contribute to the hepatic damage in COVID-19 patients; although, the drug-induced liver injury, especially idiosyncratic drug-induced liver injury, requires further causality confirmation by the updated Roussel Uclaf Causality Assessment Method published in 2016. Up to now, there is no specific regimen for COVID-19, and COVID-19-related liver injury is mainly controlled by symptomatic and supportive treatment. Here, we review the clinical features of abnormal liver enzymes in COVID-19 and pathogenesis of COVID-19-related liver injury based on the current evidence, which may provide help for clinicians and researchers in exploring the pathogenesis and developing treatment strategies.
Keywords: Abnormal liver enzymes; Clinical characteristics; Coronavirus disease 2019; Idiosyncratic drug-induced liver injury; Liver injury; Roussel Uclaf Causality Assessment Method.
. 2021 Apr 28;9(2):239-246.
doi: 10.14218/JCTH.2020.00126. Epub 2021 Apr 25.
Progress in the Clinical Features and Pathogenesis of Abnormal Liver Enzymes in Coronavirus Disease 2019
Haiyan Wu[SUP] 1 [/SUP], Shuzhong Liu[SUP] 1 [/SUP], Hesheng Luo[SUP] 1 [/SUP], Mingkai Chen[SUP] 1 [/SUP]
Affiliations
- PMID: 34007806
- PMCID: PMC8111107
- DOI: 10.14218/JCTH.2020.00126
Abstract
With the rapid development of research on coronavirus disease 2019 (COVID-19), more and more attention has been drawn to its damage to extrapulmonary organs. There are increasing lines of evidence showing that liver injury is closely related to the severity of COVID-19, which may have an adverse impact on the progression and prognosis of the patients. What is more, severe acute respiratory syndrome coronavirus-2 infection, cytokine storm, ischemia/hypoxia reperfusion injury, aggravation of the primary liver disease and drug-induced liver injury may all contribute to the hepatic damage in COVID-19 patients; although, the drug-induced liver injury, especially idiosyncratic drug-induced liver injury, requires further causality confirmation by the updated Roussel Uclaf Causality Assessment Method published in 2016. Up to now, there is no specific regimen for COVID-19, and COVID-19-related liver injury is mainly controlled by symptomatic and supportive treatment. Here, we review the clinical features of abnormal liver enzymes in COVID-19 and pathogenesis of COVID-19-related liver injury based on the current evidence, which may provide help for clinicians and researchers in exploring the pathogenesis and developing treatment strategies.
Keywords: Abnormal liver enzymes; Clinical characteristics; Coronavirus disease 2019; Idiosyncratic drug-induced liver injury; Liver injury; Roussel Uclaf Causality Assessment Method.